Join Us in the Fight Against C. difficile Colitis
LPOXY Therapeutics is pioneering a breakthrough approach to prevent C. difficile infections, a life-threatening and urgent public health threat. With a pivotal-caliber Phase 2 clinical trial planned in Australia and a 505(b)(2) regulatory pathway, we are actively engaging with venture capital firms, institutional investors, and strategic partners to accelerate our development.
Why Invest in LPOXY?
✔ Unmet Medical Need: No competing approved drugs exist for the prevention of C. difficile infections, leaving a multi-billion-dollar market opportunity.
✔ Regulatory Strategy: Our 505(b)(2) pathway leverages existing clinical data, reducing risk and time to market.
✔ Clinical & Commercial Readiness: With robust preclinical and Phase 1 safety data, we are well-positioned to advance into pivotal Phase 2 trials.
✔ Scalable Market Impact: C. difficile infections affect nearly 500,000 people annually in the U.S., with substantial unmet demand in global markets, including China and the EU.
Partner with US
We welcome discussions with venture capital firms, institutional investors, and pharmaceutical partners interested in strategic investment, licensing, or co-development opportunities. If you would like to explore an investment or partnership, please reach out.